Skip to content
2000
image of From Molecules to Medicine: Investigating the Evolution of Chemical Entities for Therapeutic Use through QSAR Analysis

Abstract

Quantitative Structure-Activity Relationship (QSAR) is a computer-based tool that depicts empirical aspects in drug modeling. While it was limited to physical organic chemistry for the past fifty years, QSAR modeling has been diversified and has become more challenging, especially in drug design. From physicochemical property prediction to toxicity predictions, ADME properties, and data mining, it has changed the perspective in drug designing. This innovation was much needed in drug design due to the increasing complexity of the process, which demands more proficient tools and a lower probability of errors. However, when it comes to challenges like predicting potency, fast structure-activity generation, and series design, QSAR has much to offer in the near future. This article aims to give an overview of modern drug chemistry and the importance of various QSAR approaches in drug designing across various fields. The present manuscript discusses the application of QSAR methods in drug design and development, along with a historical overview of various QSAR approaches, supported by relevant examples.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cpd/10.2174/0113816128392784250801044920
2026-03-05
2026-03-08

  • From This Site

    /content/journals/cpd/10.2174/0113816128392784250801044920
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Gupta S.P. QSAR studies on enzyme inhibitors. Chem. Rev. 1987 87 5 1183 1253 10.1021/cr00081a014
    [Google Scholar]
  2. Agrawal V.K. Srivastava R. Khadikar P.V. QSAR Studies on some antimalarial sulfonamides. Bioorg. Med. Chem. 2001 9 12 3287 3293 10.1016/S0968‑0896(01)00241‑3 11711304
    [Google Scholar]
  3. Lu M. Yin J. Zhu Q. Artificial intelligence in pharmaceutical sciences. Engineering (Beijing) 2023 27 37 69 10.1016/j.eng.2023.01.014
    [Google Scholar]
  4. Czermiński R. Yasri A. Hartsough D. Use of support vector machine in pattern classification: Application to QSAR studies. Quant. Struct.-Act. Relationsh. 2001 20 3 227 240 10.1002/1521‑3838(200110)20:3<227:AID‑QSAR227>3.0.CO;2‑Y
    [Google Scholar]
  5. Cherkasov A. Muratov E.N. Fourches D. QSAR modeling: where have you been? Where are you going to? J. Med. Chem. 2014 57 12 4977 5010 10.1021/jm4004285 24351051
    [Google Scholar]
  6. Devillers J. Chambon P. Zakarya D. Chastrette M. A new approach in ecotoxicological QSAR studies. Chemosphere 1986 15 8 993 1002 10.1016/0045‑6535(86)90552‑7
    [Google Scholar]
  7. Kumar A. Narasimhan B. Kumar D. Synthesis, antimicrobial, and QSAR studies of substituted benzamides. Bioorg. Med. Chem. 2007 15 12 4113 4124 10.1016/j.bmc.2007.03.074 17428669
    [Google Scholar]
  8. Mahapatra M.K. Karuppasamy M. Fundamental considerations in drug design. Computer Aided Drug Design (CADD): From Ligand-Based Methods to Structure-Based Approaches. Elsevier 2022 17 55 10.1016/B978‑0‑323‑90608‑1.00005‑8
    [Google Scholar]
  9. Sharma O.P. Gupta V. Sachdeva K. Saini N.K. Arya H. Evolutionary history of QSAR: A review. J Nat Conscientia 2011 2011 266 272
    [Google Scholar]
  10. Kubinyi H. From narcosis to hyperspace: The history of QSAR. Quant. Struct.-Act. Relationsh. 2002 21 4 348 356 10.1002/1521‑3838(200210)21:4<348:AID‑QSAR348>3.0.CO;2‑D
    [Google Scholar]
  11. Gramatica P. A short history OF QSAR evolution. 2014 Available from: https://www.researchgate.net/citation/252172555_A_SHORT_HISTORY_OF_QSAR_EVOLUTION
  12. Nichols D. CNS Stimulants. Burger’s Medicinal Chemistry and Drug Discovery. Wiley 2003 89 120 10.1002/0471266949.bmc096
    [Google Scholar]
  13. Tan H Jin J Fang C Deep learning in environmental toxicology: Current progress and open challenges 2024 4 3 805 819 10.1021/acsestwater.3c00152
    [Google Scholar]
  14. Liao S.Y. Qian L. Lu H.L. Shen Y. Zheng K.C. A combined 2D- and 3D-QSAR study on analogues of ARC-111 with antitumor activity. QSAR Comb. Sci. 2008 27 6 740 749 10.1002/qsar.200730154
    [Google Scholar]
  15. Danishuddin, Khan AU. Descriptors and their selection methods in QSAR analysis: paradigm for drug design. Drug Discov. Today 2016 21 8 1291 1302 10.1016/j.drudis.2016.06.013 27326911
    [Google Scholar]
  16. Rana T. Behl T. Sehgal A. Srivastava P. Bungau S. Unfolding the role of BDNF as a biomarker for treatment of depression. J. Mol. Neurosci. 2020 71 2008 10.1007/s12031‑020‑01754‑x
    [Google Scholar]
  17. Charaya N. Pandita D. Grewal A.S. Lather V. Design, synthesis and biological evaluation of novel thiazol-2-yl benzamide derivatives as glucokinase activators. Comput. Biol. Chem. 2018 73 221 229 10.1016/j.compbiolchem.2018.02.018 29518630
    [Google Scholar]
  18. Kubinyi H. QSAR: Hansch analysis and related approaches. QSAR: Hansch Analysis and Related Approaches. 1993 1 240 10.1002/9783527616824.ch4
    [Google Scholar]
  19. Kubinyi H. Free Wilson Analysis. Theory, applications and its relationship to hansch analysis. Quant. Struct.-Act. Relationsh. 1988 7 3 121 133 10.1002/qsar.19880070303
    [Google Scholar]
  20. Patel H.M. Noolvi M.N. Sharma P. Quantitative structure-activity relationship (QSAR) studies as strategic approach in drug discovery. Med. Chem. Res. 2014 23 12 4991 5007 10.1007/s00044‑014‑1072‑3
    [Google Scholar]
  21. Ghemtio L. Zhang Y. Xhaard H. CoMFA/CoMSIA and pharmacophore modelling as powerful tools for efficient virtual screening: Application to anti-leishmanial betulin derivatives. Virtual Screening. Rijeka, Croatia InTech 2012 147 170 10.5772/36690
    [Google Scholar]
  22. Gunda S.K. Mutya S.S. Durgam S. Adepu S. Shaik M. Application of 3D QSAR CoMFA/CoMSIA and in silico docking studies on potent inhibitors of interleukin-2 inducible T-cell kinase (ITK). Int. J. Pharm. Sci. Rev. Res. 2015 30 28 34
    [Google Scholar]
  23. Verma J. Khedkar V. Coutinho E. 3D-QSAR in drug design: A review. Curr. Top. Med. Chem. 2010 10 1 95 115 10.2174/156802610790232260 19929826
    [Google Scholar]
  24. Cronin M.T.D. Quantitative structure-activity relationships (QSARs) - Applications and methodology. Challeng Adv Computat Chem Physics 2010 8 3 11 10.1007/978‑1‑4020‑9783‑6_1
    [Google Scholar]
  25. Jenssen H.Å. Fjell C.D. Cherkasov A. Hancock R.E.W. QSAR modeling and computer-aided design of antimicrobial peptides. J. Pept. Sci. 2008 14 1 110 114 10.1002/psc.908 17847019
    [Google Scholar]
  26. Jenssen H. Gutteberg T.J. Lejon T. Modelling of anti-HSV activity of lactoferricin analogues using amino acid descriptors. J. Pept. Sci. 2005 11 2 97 103 10.1002/psc.604 15635641
    [Google Scholar]
  27. Jenssen H. Gutteberg T.J. Rekdal Ø. Lejon T. Prediction of activity, synthesis and biological testing of anti-HSV active peptides. Chem. Biol. Drug Des. 2006 68 1 58 66 10.1111/j.1747‑0285.2006.00412.x 16923027
    [Google Scholar]
  28. Lejon T. Strøm M.B. Svendsen J.S. Antibiotic activity of pentadecapeptides modelled from amino acid descriptors. J. Pept. Sci. 2001 7 2 74 81 10.1002/psc.295 11277499
    [Google Scholar]
  29. Lejon T. Stiberg T. Strøm M.B. Svendsen J.S. Prediction of antibiotic activity and synthesis of new pentadecapeptides based on lactoferricins. J. Pept. Sci. 2004 10 6 329 335 10.1002/psc.553 15214437
    [Google Scholar]
  30. Yang N. Lejon T. Rekdal Ø. Antitumour activity and specificity as a function of substitutions in the lipophilic sector of helical lactoferrin-derived peptide. J. Pept. Sci. 2003 9 5 300 311 10.1002/psc.457 12803496
    [Google Scholar]
  31. Jenssen H. Lejon T. Hilpert K. Fjell C.D. Cherkasov A. Hancock R.E.W. Evaluating different descriptors for model design of antimicrobial peptides with enhanced activity toward P. aeruginosa. Chem. Biol. Drug Des. 2007 70 2 134 142 10.1111/j.1747‑0285.2007.00543.x 17683374
    [Google Scholar]
  32. Kauppi A.M. Andersson C.D. Norberg H.A. Sundin C. Linusson A. Elofsson M. Inhibitors of type III secretion in Yersinia: Design, synthesis and multivariate QSAR of 2-arylsulfonylamino-benzanilides. Bioorg. Med. Chem. 2007 15 22 6994 7011 10.1016/j.bmc.2007.07.047 17851084
    [Google Scholar]
  33. Wold S. Sjöström M. Eriksson L. PLS-regression: A basic tool of chemometrics. Chemom. Intell. Lab. Syst. 2001 58 2 109 130 10.1016/S0169‑7439(01)00155‑1
    [Google Scholar]
  34. Lindgren F. Hansen B. Karcher W. Sjöström M. Eriksson L. Model validation by permutation tests: Applications to variable selection. J. Chemometr. 1996 10 5-6 521 532 10.1002/(SICI)1099‑128X(199609)10:5/6<521:AID‑CEM448>3.0.CO;2‑J
    [Google Scholar]
  35. El Zoeiby A. Sanschagrin F. Levesque R.C. Structure and function of the Mur enzymes: Development of novel inhibitors. Mol. Microbiol. 2003 47 1 1 12 10.1046/j.1365‑2958.2003.03289.x 12492849
    [Google Scholar]
  36. Cramer R.D. Patterson D.E. Bunce J.D. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc. 1988 110 18 5959 5967 10.1021/ja00226a005 22148765
    [Google Scholar]
  37. Datar P.A. Khedkar S.A. Malde A.K. Coutinho E.C. Comparative residue interaction analysis (CoRIA): A 3D-QSAR approach to explore the binding contributions of active site residues with ligands. J. Comput. Aided Mol. Des. 2006 20 6 343 360 10.1007/s10822‑006‑9051‑5 17009094
    [Google Scholar]
  38. Stahl M. Böhm H.J. Development of filter functions for protein-ligand docking. J. Mol. Graph. Model. 1998 16 3 121 132 10.1016/S1093‑3263(98)00018‑7 10434251
    [Google Scholar]
  39. Narasimhan B. Kothawade’ R. Pharande D.S. Mouryaa V.K. Dhake A.S. Syntheses and QSAR studies of sorbic, cinnamic and ricinoleic acid derivatives as potential antibacterial agents. Indian J. Chem. 2003 428 2828 2834
    [Google Scholar]
  40. Narasimhan B. Belsare D. Pharande D. Mourya V. Dhake A. Esters, amides and substituted derivatives of cinnamic acid: Synthesis, antimicrobial activity and QSAR investigations. Eur. J. Med. Chem. 2004 39 10 827 834 10.1016/j.ejmech.2004.06.013 15464616
    [Google Scholar]
  41. Böhm H.J. Prediction of binding constants of protein ligands: A fast method for the prioritization of hits obtained from de novo design or 3D database search programs. J. Comput. Aided Mol. Des. 1998 12 4 309 323 10.1023/A:1007999920146 9777490
    [Google Scholar]
  42. Böhm H-J. The development of a simple empirical scoring function to estimate the binding constant for a protein-ligand complex of known three-dimensional structure. J. Comput. Aided Mol. Des. 1994 8 3 243 256 10.1007/BF00126743 7964925
    [Google Scholar]
  43. Böhm H-J. On the use of LUDI to search the fine chemicals directory for ligands of proteins of known three-dimensional structure. J. Comput. Aided Mol. Des. 1994 8 5 623 632 10.1007/BF00123669 7876904
    [Google Scholar]
  44. Böhm H-J. The computer program LUDI: A new method for the de novo design of enzyme inhibitors. J. Comput. Aided Mol. Des. 1992 6 1 61 78 10.1007/BF00124387 1583540
    [Google Scholar]
  45. Böhm H-J. LUDI: rule-based automatic design of new substituents for enzyme inhibitor leads. J. Comput. Aided Mol. Des. 1992 6 6 593 606 10.1007/BF00126217 1291628
    [Google Scholar]
  46. Böhm H.J. A novel computational tool for automated structure-based drug design. J. Mol. Recognit. 1993 6 3 131 137 10.1002/jmr.300060305 8060670
    [Google Scholar]
  47. Khedkar S.A. Malde A.K. Coutinho E.C. Design of inhibitors of the MurF enzyme of Streptococcus pneumoniae using docking, 3D-QSAR, and de Novo design. J. Chem. Inf. Model. 2007 47 5 1839 1846 10.1021/ci600568u 17663541
    [Google Scholar]
  48. Narasimhan B. Mourya V. Dhake A. Design, synthesis, antibacterial, and QSAR studies of myristic acid derivatives. Bioorg. Med. Chem. Lett. 2006 16 11 3023 3029 10.1016/j.bmcl.2006.02.056 16554156
    [Google Scholar]
  49. Kuz’min V.E. Artemenko A.G. Polischuk P.G. Hierarchic system of QSAR models (1D-4D) on the base of simplex representation of molecular structure. J. Mol. Model. 2005 11 6 457 467 10.1007/s00894‑005‑0237‑x 16237516
    [Google Scholar]
  50. Rännar S. Lindgren F. Geladi P. Wold S. A PLS kernel algorithm for data sets with many variables and fewer objects. Part 1: Theory and algorithm. J. Chemometr. 1994 8 2 111 125 10.1002/cem.1180080204
    [Google Scholar]
  51. Artemenko A.G. Muratov E.N. Atamanyuk D.V. QSAR analysis of antimicrobial activity of 4-thiazolidone derivatives. QSAR Comb. Sci. 2009 28 2 194 205 10.1002/qsar.200860035
    [Google Scholar]
  52. Nandi S. Bagchi M.C. 3D-QSAR and molecular docking studies of 4-anilinoquinazoline derivatives: A rational approach to anticancer drug design. Mol. Divers. 2010 14 1 27 38 10.1007/s11030‑009‑9137‑9 19330460
    [Google Scholar]
  53. Blume-Jensen P. Hunter T. Oncogenic kinase signalling. Nature 2001 411 6835 355 365 10.1038/35077225 11357143
    [Google Scholar]
  54. Nandi S. Bagchi M.C. QSAR of aminopyrido[2,3-d]pyrimidin-7-yl derivatives: Anticancer drug design by computed descriptors. J. Enzyme Inhib. Med. Chem. 2009 24 4 937 948 10.1080/14756360802519327 19555178
    [Google Scholar]
  55. Nandi S. Bagchi M.C. QSAR Analysis of BABQ compounds via calculated molecular descriptors. Med. Chem. Res. 2007 15 7-8 393 406 10.1007/s00044‑006‑0010‑4
    [Google Scholar]
  56. Ghosh P. Thanadath M. Bagchi M.C. On an aspect of calculated molecular descriptors in QSAR studies of quinolone antibacterials. Mol. Divers. 2006 10 3 415 427 10.1007/s11030‑006‑9018‑4 16896544
    [Google Scholar]
  57. Cho S.J. Tropsha A. Cross-validated R2-guided region selection for comparative molecular field analysis: A simple method to achieve consistent results. J. Med. Chem. 1995 38 7 1060 1066 10.1021/jm00007a003 7707309
    [Google Scholar]
  58. Clark M. Cramer R.D. Van Opdenbosch N. Validation of the general purpose tripos 5.2 force field. J. Comput. Chem. 1989 10 8 982 1012 10.1002/jcc.540100804
    [Google Scholar]
  59. Saqib U. Siddiqi M.I. 3D-QSAR studies on triazolopiperazine amide inhibitors of dipeptidyl peptidase-IV as anti-diabetic agents. SAR QSAR Environ. Res. 2009 20 5-6 519 535 10.1080/10629360903278677 19916112
    [Google Scholar]
  60. Bush B.L. Nachbar R.B. Sample-distance partial least squares: PLS optimized for many variables, with application to CoMFA. J. Comput. Aided Mol. Des. 1993 7 5 587 619 10.1007/BF00124364 8294948
    [Google Scholar]
  61. Schmidt F. Matter H. Hessler G. Czich A. Predictive in silico off-target profiling in drug discovery. Future Med. Chem. 2014 6 3 295 317 10.4155/fmc.13.202 24575966
    [Google Scholar]
  62. Noolvi M. Patel H. Bhardwaj V. 2D QSAR studies on a series of 4-anilino quinazoline derivatives as tyrosine kinase (EGFR) inhibitor: An approach to design anticancer agents. Dig. J. Nanomater. Biostruct. 2010 5 387 401
    [Google Scholar]
  63. Bridges A.J. Zhou H. Cody D.R. Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor. J. Med. Chem. 1996 39 1 267 276 10.1021/jm9503613 8568816
    [Google Scholar]
  64. Fabbro D. Ruetz S. Buchdunger E. Protein kinases as targets for anticancer agents: From inhibitors to useful drugs. Pharmacol. Ther. 2002 93 2-3 79 98 10.1016/S0163‑7258(02)00179‑1 12191602
    [Google Scholar]
  65. Mullen L. Duchowicz P. Castro E. QSAR treatment on a new class of triphenylmethyl-containing compounds as potent anticancer agents. Chemom. Intell. Lab. Syst. 2011 107 2 269 275 10.1016/j.chemolab.2011.04.011
    [Google Scholar]
  66. Palchaudhuri R. Hergenrother P.J. Triphenylmethylamides (TPMAs): Structure-activity relationship of compounds that induce apoptosis in melanoma cells. Bioorg. Med. Chem. Lett. 2008 18 22 5888 5891 10.1016/j.bmcl.2008.07.128 18710803
    [Google Scholar]
  67. García J. Duchowicz P.R. Rozas M.F. A comparative QSAR on 1,2,5-thiadiazolidin-3-one 1,1-dioxide compounds as selective inhibitors of human serine proteinases. J. Mol. Graph. Model. 2011 31 10 19 10.1016/j.jmgm.2011.07.007 21908217
    [Google Scholar]
  68. Palchaudhuri R. Nesterenko V. Hergenrother P.J. The complex role of the triphenylmethyl motif in anticancer compounds. J. Am. Chem. Soc. 2008 130 31 10274 10281 10.1021/ja8020999 18611022
    [Google Scholar]
  69. Al-Rashood S.T. Aboldahab I.A. Nagi M.N. Synthesis, dihydrofolate reductase inhibition, antitumor testing, and molecular modeling study of some new 4(3H)-quinazolinone analogs. Bioorg. Med. Chem. 2006 14 24 8608 8621 10.1016/j.bmc.2006.08.030 16971132
    [Google Scholar]
  70. Lohray B.B. Gandhi N. Srivastava B.K. Lohray V.B. 3D QSAR studies of N-4-arylacryloylpiperazin-1-yl-phenyl-oxazolidinones: A novel class of antibacterial agents. Bioorg. Med. Chem. Lett. 2006 16 14 3817 3823 10.1016/j.bmcl.2006.04.023 16650983
    [Google Scholar]
  71. Kumar D. Kapoor A. Thangadurai A. Kumar P. Narasimhan B. Synthesis, antimicrobial evaluation and QSAR studies of 3-ethoxy-4-hydroxybenzylidene/4-nitrobenzylidene hydrazides. Chin. Chem. Lett. 2011 22 11 1293 1296 10.1016/j.cclet.2011.06.014
    [Google Scholar]
  72. Sigroha S. Narasimhan B. Kumar P. Design, synthesis,] antimicrobial, anticancer evaluation, and QSAR studies of] 4-(substituted benzylidene-amino)-1,5-dimethyl-2-phenyl-1,2-dihydropyrazol-3-ones. Med. Chem. Res. 2012 21 11 3863 3875 10.1007/s00044‑011‑9906‑8
    [Google Scholar]
  73. Speck-Planche A. Kleandrova V.V. Luan F. Cordeiro M.N.D.S. Rational drug design for anti-cancer chemotherapy: Multi-target QSAR models for the in silico discovery of anti-colorectal cancer agents. Bioorg. Med. Chem. 2012 20 15 4848 4855 10.1016/j.bmc.2012.05.071 22750007
    [Google Scholar]
  74. Noolvi M.N. Patel H.M. Bhardwaj V. A comparative QSAR analysis of quinazoline analogues as tyrosine kinase (erbB-2) inhibitors. Med. Chem. 2011 7 3 200 212 10.2174/157340611795564213 21486203
    [Google Scholar]
  75. Hubatsch I. Ragnarsson E.G.E. Artursson P. Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers. Nat. Protoc. 2007 2 9 2111 2119 10.1038/nprot.2007.303 17853866
    [Google Scholar]
  76. Nandi S. Bagchi M.C. QSAR modeling of 4-anilinofuro[2,3-b]quinolines: An approach to anticancer drug design. Med. Chem. Res. 2014 23 4 1672 1682 10.1007/s00044‑013‑0759‑1
    [Google Scholar]
  77. Lee S Lee IH Kim HJ Chang GS Chung JE No KT The Pre- ADME approach: Web-based program for rapid prediction of physico-chemical, drug absorption and drug-like properties. Euro QSAR 2002 - Designing Drugs and Crop Protectants: Processes, Problems and Solutions. Bologna, Italy, 8-13 September 2002 418 420
    [Google Scholar]
  78. Pourbasheer E. Amanlou M. 3D-QSAR analysis of anti-cancer agents by CoMFA and CoMSIA. Med. Chem. Res. 2014 23 2 800 809 10.1007/s00044‑013‑0676‑3
    [Google Scholar]
  79. Feroz Khan F. Alam S. QSAR and docking studies on xanthone derivatives for anticancer activity targeting DNA topoisomerase IIα. Drug Des. Devel. Ther. 2014 8 183 195 10.2147/DDDT.S51577 24516330
    [Google Scholar]
  80. Veselinović A.M. Toropov A. Toropova A. Stanković-Đorđević D. Veselinović J.B. Design and development of novel antibiotics based on FtsZ inhibition - in silico studies. New J. Chem. 2018 42 13 10976 10982 10.1039/C8NJ01034J
    [Google Scholar]
  81. Ravichandran V. Harish R. QSAR studies on imidazoles and sulfonamides as antidiabetic agents. An. Univ. Ovidius Constanta Ser. Chim. 2019 30 1 5 13 10.2478/auoc‑2019‑0002
    [Google Scholar]
  82. Ahamad S. Islam A. Ahmad F. Dwivedi N. Hassan M.I. 2/3D-QSAR, molecular docking and MD simulation studies of FtsZ protein targeting benzimidazoles derivatives. Comput. Biol. Chem. 2019 78 398 413 10.1016/j.compbiolchem.2018.12.017 30602415
    [Google Scholar]
  83. Alam S. Khan F. 3D-QSAR, Docking, ADME/Tox studies on Flavone analogs reveal anticancer activity through Tankyrase inhibition. Sci. Rep. 2019 9 1 5414 10.1038/s41598‑019‑41984‑7 30932078
    [Google Scholar]
  84. Al-Sha’er M.A. Al-Balas Q.A. Hassan M.A. Al Jabal G.A. Almaaytah A.M. Combination of pharmacophore modeling and 3D-QSAR analysis of potential glyoxalase-I inhibitors as anticancer agents. Comput. Biol. Chem. 2019 80 102 110 10.1016/j.compbiolchem.2019.03.011 30947068
    [Google Scholar]
  85. Babu S. Nagarajan S.K. Madhavan T. Understanding the structural features of JAK2 inhibitors: A combined 3D-QSAR, DFT and molecular dynamics study. Mol. Divers. 2019 23 4 845 874 10.1007/s11030‑018‑09913‑4 30617940
    [Google Scholar]
  86. Balasubramanian P.K. Balupuri A. Bhujbal S.P. Cho S.J. 3D-QSAR-aided design of potent c-Met inhibitors using molecular dynamics simulation and binding free energy calculation. J. Biomol. Struct. Dyn. 2019 37 8 2165 2178 10.1080/07391102.2018.1479309 30044205
    [Google Scholar]
  87. Bhuvaneshwari S. Sankaranarayanan K. Identification of potential CRAC channel inhibitors: Pharmacophore mapping, 3D-QSAR modelling, and molecular docking approach. SAR QSAR Environ. Res. 2019 30 2 81 108 10.1080/1062936X.2019.1566172 30773908
    [Google Scholar]
  88. O Salas C Zarate AM Kryštof V Promising 2,6,9-Trisubstituted purine derivatives for anticancer compounds: Synthesis, 3D-QSAR, and preliminary biological assays. Int. J. Mol. Sci. 2019 21 1 161 10.3390/ijms21010161 31881717
    [Google Scholar]
  89. Chu H. He Q. Wang J. 3D-QSAR, molecular docking, and molecular dynamics simulation of a novel thieno[3,4-d]pyrimidine inhibitor targeting human immunodeficiency virus type 1 reverse transcriptase. J. Biomol. Struct. Dyn. 2020 38 15 4567 4578 10.1080/07391102.2019.1697366 31760877
    [Google Scholar]
  90. Dowlati Beirami A. Hajimahdi Z. Zarghi A. Docking-based 3D-QSAR (CoMFA, CoMFA-RG, CoMSIA) study on hydroquinoline and thiazinan-4-one derivatives as selective COX-2 inhibitors. J. Biomol. Struct. Dyn. 2019 37 11 2999 3006 10.1080/07391102.2018.1502687 30035675
    [Google Scholar]
  91. El-Hassab M.A.E.M. El-Bastawissy E.E. El-Moselhy T.F. Identification of potential inhibitors for HCV NS5b of genotype 4a by combining dynamic simulation, protein-ligand interaction fingerprint, 3D pharmacophore, docking and 3D QSAR. J. Biomol. Struct. Dyn. 2020 38 15 4521 4535 10.1080/07391102.2019.1685005 31647392
    [Google Scholar]
  92. Elrhayam Y. Elharfi A. 3D-QSAR studies of the chemical modification of hydroxyl groups of biomass (cellulose, hemicelluloses and lignin) using quantum chemical descriptors. Heliyon 2019 5 8 e02173 10.1016/j.heliyon.2019.e02173 31485496
    [Google Scholar]
  93. Fan F. Toledo Warshaviak D. Hamadeh H.K. Dunn R.T. The integration of pharmacophore-based 3D QSAR modeling and virtual screening in safety profiling: A case study to identify antagonistic activities against adenosine receptor, A2A, using 1,897 known drugs. PLoS One 2019 14 1 e0204378 10.1371/journal.pone.0204378 30605479
    [Google Scholar]
  94. Floresta G. Cilibrizzi A. Abbate V. Spampinato A. Zagni C. Rescifina A. 3D-QSAR assisted identification of FABP4 inhibitors: An effective scaffold hopping analysis/QSAR evaluation. Bioorg. Chem. 2019 84 276 284 10.1016/j.bioorg.2018.11.045 30529845
    [Google Scholar]
  95. Floresta G. Cilibrizzi A. Abbate V. Spampinato A. Zagni C. Rescifina A. FABP4 inhibitors 3D-QSAR model and isosteric replacement of BMS309403 datasets. Data Brief 2019 22 471 483 10.1016/j.dib.2018.12.047 30619925
    [Google Scholar]
  96. Gao Y. Wang H. Wang J. Cheng M. In silico studies on p21-activated kinase 4 inhibitors: comprehensive application of 3D-QSAR analysis, molecular docking, molecular dynamics simulations, and MM-GBSA calculation. J. Biomol. Struct. Dyn. 2020 38 14 4119 4133 10.1080/07391102.2019.1673823 31556340
    [Google Scholar]
  97. Ghaleb A. In silico exploration of aryl halides analogues as checkpoint kinase 1 inhibitors by using 3D QSAR, molecular docking study, and ADMET screening. Adv. Pharm. Bull. 2019 9 84 92 10.15171/apb.2019.011
    [Google Scholar]
  98. Ginex T. Vazquez J. Gilbert E. Herrero E. Luque F.J. Lipophilicity in drug design: an overview of lipophilicity descriptors in 3D-QSAR studies. Future Med. Chem. 2019 11 10 1177 1193 10.4155/fmc‑2018‑0435 30799643
    [Google Scholar]
  99. Gu W. Li Q. Li Y. Environment-friendly PCN derivatives design and environmental behavior simulation based on a multi-activity 3D-QSAR model and molecular dynamics. J. Hazard. Mater. 2020 393 122339 10.1016/j.jhazmat.2020.122339 32135364
    [Google Scholar]
  100. Gu X. Wang Y. Wang M. Wang J. Li N. Computational investigation of imidazopyridine analogs as protein kinase B (Akt1) allosteric inhibitors by using 3D-QSAR, molecular docking and molecular dynamics simulations. J. Biomol. Struct. Dyn. 2021 39 1 63 78 10.1080/07391102.2019.1705185 31838955
    [Google Scholar]
  101. Gupta N. Vyas V.K. Patel B.D. Ghate M. Design of 2-Nitroimidazooxazine derivatives as deazaflavin-dependent nitroreductase (ddn) activators as anti-mycobacterial agents based on 3D QSAR, HQSAR, and docking study with in silico prediction of activity and toxicity. Interdiscip. Sci. 2019 11 2 191 205 10.1007/s12539‑017‑0256‑1 28895050
    [Google Scholar]
  102. Jayaraj J.M. Krishnasamy G. Lee J.K. Muthusamy K. In silico identification and screening of CYP24A1 inhibitors: 3D QSAR pharmacophore mapping and molecular dynamics analysis. J. Biomol. Struct. Dyn. 2019 37 7 1700 1714 10.1080/07391102.2018.1464958 29658431
    [Google Scholar]
  103. Joseph O.A. Babatomiwa K. Niyi A. Olaposi O. Olumide I. Molecular docking and 3D Qsar studies of C000000956 as a potent inhibitor of Bace-1. Drug Res. (Stuttg.) 2019 69 8 451 457 10.1055/a‑0849‑9377 30780168
    [Google Scholar]
  104. Kang G.Q. Duan W.G. Lin G.S. Yu Y.P. Wang X.Y. Lu S.Z. Synthesis, antifungal activity and 3D-QSAR study of (Z)- and (E)-3-caren-5-one oxime sulfonates. Molecules 2019 24 3 477 10.3390/molecules24030477
    [Google Scholar]
  105. Khan M.F. Verma G. Alam P. Dibenzepinones, dibenzoxepines and benzosuberones based p38α MAP kinase inhibitors: Their pharmacophore modelling, 3D-QSAR and docking studies. Comput. Biol. Med. 2019 110 175 185 10.1016/j.compbiomed.2019.05.023 31173941
    [Google Scholar]
  106. Khan N. Halim S.A. Khan W. Zafar S.K. Ul-Haq Z. In-silico designing and characterization of binding modes of two novel inhibitors for CB1 receptor against obesity by classical 3D-QSAR approach. J. Mol. Graph. Model. 2019 89 199 214 10.1016/j.jmgm.2019.03.016 30908997
    [Google Scholar]
  107. Kovačević S.Z. Karadžić M.Ž. Vukić D.V. Toward steroidal anticancer drugs: Non-parametric and 3D-QSAR modeling of 17-picolyl and 17-picolinylidene androstanes with antiproliferative activity on breast adenocarcinoma cells. J. Mol. Graph. Model. 2019 87 240 249 10.1016/j.jmgm.2018.12.010 30594032
    [Google Scholar]
  108. Li K. Zhu J. Xu L. Jin J. Rational design of novel phosphoinositide 3-Kinase Gamma (PI3Kγ) selective inhibitors: A computational investigation integrating 3D-QSAR, molecular docking and molecular dynamics simulation. Chem. Biodivers. 2019 16 7 e1900105 10.1002/cbdv.201900105 31111650
    [Google Scholar]
  109. Liu G. Wan Y. Wang W. Fang S. Gu S. Ju X. Docking-based 3D-QSAR and pharmacophore studies on diarylpyrimidines as non-nucleoside inhibitors of HIV-1 reverse transcriptase. Mol. Divers. 2019 23 1 107 121 10.1007/s11030‑018‑9860‑1 30051344
    [Google Scholar]
  110. Liu J. Feng K. Ren Y. In silico studies on potential TNKS inhibitors: A combination of pharmacophore and 3D-QSAR modelling, virtual screening, molecular docking and molecular dynamics. J. Biomol. Struct. Dyn. 2019 37 14 3803 3821 10.1080/07391102.2018.1528887 30261821
    [Google Scholar]
  111. Liu J.B. Li F.Y. Li Y.X. Synthesis, insecticidal evaluation and 3D-QSAR study of novel anthranilic diamide derivatives as potential ryanodine receptor modulators. Pest Manag. Sci. 2019 75 4 1034 1044 10.1002/ps.5213 30230239
    [Google Scholar]
  112. Liu Y.Y. Ding T.T. Feng X.Y. Xu W.R. Cheng X.C. Virtual identification of novel peroxisome proliferator-activated receptor (PPAR) α/δ dual antagonist by 3D-QSAR, molecule docking, and molecule dynamics simulation. J. Biomol. Struct. Dyn. 2020 38 14 4143 4161 10.1080/07391102.2019.1673211 31556349
    [Google Scholar]
  113. Feng X.Y. Jia W.Q. Liu X. Identification of novel PPARα/γ dual agonists by pharmacophore screening, docking analysis, ADMET prediction and molecular dynamics simulations. Comput. Biol. Chem. 2019 78 178 189 10.1016/j.compbiolchem.2018.11.023 30557816
    [Google Scholar]
  114. Lorca M. Valdes Y. Chung H. Romero-Parra J. Pessoa-Mahana C.D. Mella J. Three-dimensional quantitative structure-activity relationships (3D-QSAR) on a series of piperazine-carboxamides fatty acid amide hydrolase (FAAH) inhibitors as a useful tool for the design of new cannabinoid ligands. Int. J. Mol. Sci. 2019 20 10 2510 10.3390/ijms20102510
    [Google Scholar]
  115. Ma J. Zhang H. Zhang X. Lei M. 3D-QSAR studies of D3R antagonists and 5-HT1AR agonists. J. Mol. Graph. Model. 2019 86 132 141 10.1016/j.jmgm.2018.10.013 30359859
    [Google Scholar]
  116. Maadwar S. Galla R. Cytotoxic oxindole derivatives: In vitro EGFR inhibition, pharmacophore modeling, 3D-QSAR and molecular dynamics studies. J. Recept. Signal Transduct. Res. 2019 39 5-6 460 469 10.1080/10799893.2019.1683865 31814499
    [Google Scholar]
  117. Mali S.N. Chaudhari H.K. Molecular modelling studies on adamantane-based Ebola virus GP-1 inhibitors using docking, pharmacophore and 3D-QSAR. SAR QSAR Environ. Res. 2019 30 3 161 180 10.1080/1062936X.2019.1573377 30786763
    [Google Scholar]
  118. Manouchehrizadeh E. Mostoufi A. Tahanpesar E. Fereidoonnezhad M. Alignment-independent 3D-QSAR and molecular docking studies of tacrine-4-oxo-4H-Chromene hybrids as anti-Alzheimer’s agents. Comput. Biol. Chem. 2019 80 463 471 10.1016/j.compbiolchem.2019.05.010 31170562
    [Google Scholar]
  119. Masand V.H. Elsayed N.N. Thakur S.D. Gawhale N. Rathore M.M. Quinoxalinones based aldose reductase inhibitors: 2D and 3D-QSAR analysis. Mol. Inform. 2019 38 8-9 1800149 10.1002/minf.201800149 31131980
    [Google Scholar]
  120. Pan C. Meng H. Zhang S. Homology modeling and 3D-QSAR study of benzhydrylpiperazine δ opioid receptor agonists. Comput. Biol. Chem. 2019 83 107109 10.1016/j.compbiolchem.2019.107109 31445419
    [Google Scholar]
  121. Patel T.S. Bhatt J.D. Dixit R.B. Chudasama C.J. Patel B.D. Dixit B.C. Green synthesis, biological evaluation, molecular docking studies and 3D-QSAR analysis of novel phenylalanine linked quinazoline-4(3H)-one-sulphonamide hybrid entities distorting the malarial reductase activity in folate pathway. Bioorg. Med. Chem. 2019 27 16 3574 3586 10.1016/j.bmc.2019.06.038 31272837
    [Google Scholar]
  122. Sherin D.R. Geethu C.K. Prabhakaran J. Mann J.J. Dileep Kumar J.S. Manojkumar T.K. Molecular docking, dynamics simulations and 3D-QSAR modeling of arylpiperazine derivatives of 3,5-dioxo-(2H,4H)-1,2,4-triazine as 5-HT1AR agonists. Comput. Biol. Chem. 2019 78 108 115 10.1016/j.compbiolchem.2018.11.015 30502727
    [Google Scholar]
  123. Sitwala N.D. Vyas V.K. Gedia P. 3D QSAR-based design and liquid phase combinatorial synthesis of 1,2-disubstituted benzimidazole-5-carboxylic acid and 3-substituted-5 H -benzimidazo[1,2- d][1,4]benzodiazepin-6(7H)-one derivatives as anti-mycobacterial agents. MedChemComm 2019 10 5 817 827 10.1039/C9MD00006B 31293724
    [Google Scholar]
  124. Sobhy M.K. Mowafy S. Lasheen D.S. Farag N.A. Abouzid K.A.M. 3D-QSAR pharmacophore modelling, virtual screening and docking studies for lead discovery of a novel scaffold for VEGFR 2 inhibitors: Design, synthesis and biological evaluation. Bioorg. Chem. 2019 89 102988 10.1016/j.bioorg.2019.102988 31146197
    [Google Scholar]
  125. Sović I. Cindrić M. Perin N. Biological potential of novel methoxy and hydroxy substituted heteroaromatic amides designed as promising antioxidative agents: Synthesis, 3D-QSAR analysis, and biological activity. Chem. Res. Toxicol. 2019 32 9 1880 1892 10.1021/acs.chemrestox.9b00256 31381319
    [Google Scholar]
  126. Velázquez-Libera J.L. Caballero J. Murillo-López J.A. de la Torre A.F. Structural requirements of N-alpha-mercaptoacetyl dipeptide (NAMdP) inhibitors of Pseudomonas aeruginosa virulence factor LasB: 3D-QSAR, molecular docking, and interaction fingerprint studies. Int. J. Mol. Sci. 2019 20 24 6133 10.3390/ijms20246133
    [Google Scholar]
  127. Velázquez-Libera J.L. Rossino G. Navarro-Retamal C. Collina S. Caballero J. Docking, interaction fingerprint, and three-dimensional quantitative structure-activity relationship (3D-QSAR) of Sigma1 receptor ligands, analogs of the neuroprotective agent RC-33. Front Chem. 2019 7 496 10.3389/fchem.2019.00496 31355187
    [Google Scholar]
  128. Vucicevic J. Nikolic K. Mitchell J.B.O. Rational drug design of antineoplastic agents using 3D-QSAR, cheminformatic, and virtual screening approaches. Curr. Med. Chem. 2019 26 21 3874 3889 10.2174/0929867324666170712115411 28707592
    [Google Scholar]
  129. Vyas V.K. Qureshi G. Oza D. Synthesis of 2-,4,-6-, and/or 7-substituted quinoline derivatives as human dihydroorotate dehydrogenase (hDHODH) inhibitors and anticancer agents: 3D QSAR-assisted design. Bioorg. Med. Chem. Lett. 2019 29 7 917 922 10.1016/j.bmcl.2019.01.038 30738663
    [Google Scholar]
  130. Wang M. Li X. Chen M. 3D-QSAR based optimization of insect neuropeptide allatostatin analogs. Bioorg. Med. Chem. Lett. 2019 29 7 890 895 10.1016/j.bmcl.2019.02.001 30765188
    [Google Scholar]
  131. Wu J.W. Yin L. Liu Y.Q. Zhang H. Synthesis, biological evaluation and 3D-QSAR studies of 1,2,4-triazole-5-substituted carboxylic acid bioisosteres as uric acid transporter 1 (URAT1) inhibitors for the treatment of hyperuricemia associated with gout. Bioorg. Med. Chem. Lett. 2019 29 3 383 388 10.1016/j.bmcl.2018.12.036
    [Google Scholar]
  132. Wu R.J. Ren T. Gao J.Y. Chemical preparation, biological evaluation and 3D-QSAR of ethoxysulfuron derivatives as novel antifungal agents targeting acetohydroxyacid synthase. Eur. J. Med. Chem. 2019 162 348 363 10.1016/j.ejmech.2018.11.005 30448420
    [Google Scholar]
  133. Yang J. Gu W. Li Y. Biological enrichment prediction of polychlorinated biphenyls and novel molecular design based on 3D-QSAR/HQSAR associated with molecule docking. Biosci. Rep. 2019 39 5 BSR20180409 10.1042/BSR20180409 31101726
    [Google Scholar]
  134. Yue Y. Geng S. Shi Y. Liang G. Wang J. Liu B. Interaction mechanism of flavonoids and zein in ethanol-water solution based on 3D-QSAR and spectrofluorimetry. Food Chem. 2019 276 776 781 10.1016/j.foodchem.2018.10.083 30409662
    [Google Scholar]
  135. Zhang X. Mao J. Li W. Koike K. Wang J. Improved 3D-QSAR prediction by multiple-conformational alignment: A case study on PTP1B inhibitors. Comput. Biol. Chem. 2019 83 107134 10.1016/j.compbiolchem.2019.107134 31629257
    [Google Scholar]
  136. Zięba A. Żuk J. Bartuzi D. Matosiuk D. Poso A. Kaczor A.A. The universal 3D QSAR model for dopamine D2 receptor antagonists. Int. J. Mol. Sci. 2019 20 18 4555 10.3390/ijms20184555 31540025
    [Google Scholar]
  137. Alizadeh A.A. Jafari B. Dastmalchi S. Alignment independent 3D-QSAR studies and molecular dynamics simulations for the identification of potent and selective S1P1 receptor agonists. J. Mol. Graph. Model. 2020 94 107459 10.1016/j.jmgm.2019.107459 31589999
    [Google Scholar]
  138. Azam M.A. Thathan J. Jupudi S. Pharmacophore modeling, atom based 3D-QSAR, molecular docking and molecular dynamics studies on Escherichia coli ParE inhibitors. Comput. Biol. Chem. 2020 84 107197 10.1016/j.compbiolchem.2019.107197 31901788
    [Google Scholar]
  139. Floresta G. Patamia V. Gentile D. Repurposing of FDA-approved drugs for treating iatrogenic botulism: A paired 3D-QSAR/Docking approach †. ChemMedChem 2020 15 2 256 262 10.1002/cmdc.201900594 31774239
    [Google Scholar]
  140. Kumar A. Rathi E. Kini S.G. Identification of potential tumour-associated carbonic anhydrase isozyme IX inhibitors: atom-based 3D-QSAR modelling, pharmacophore-based virtual screening and molecular docking studies. J. Biomol. Struct. Dyn. 2020 38 7 2156 2170 10.1080/07391102.2019.1626285 31179854
    [Google Scholar]
  141. Liu J. Zhu Y. He Y. Combined pharmacophore modeling, 3D-QSAR and docking studies to identify novel HDAC inhibitors using drug repurposing. J. Biomol. Struct. Dyn. 2020 38 2 533 547 10.1080/07391102.2019.1590241 30938574
    [Google Scholar]
  142. Perry C.K. Casey A.B. Felsing D.E. Synthesis of novel 5-substituted-2-aminotetralin analogs: 5-HT1A and 5-HT7 G protein-coupled receptor affinity, 3D-QSAR and molecular modeling. Bioorg. Med. Chem. 2020 28 3 115262 10.1016/j.bmc.2019.115262 31882369
    [Google Scholar]
  143. Wang Y. Feng S. Gao H. Wang J. Computational investigations of gram-negative bacteria phosphopantetheine adenylyltransferase inhibitors using 3D-QSAR, molecular docking and molecular dynamic simulations. J. Biomol. Struct. Dyn. 2020 38 5 1435 1447 10.1080/07391102.2019.1608305 31038397
    [Google Scholar]
  144. Zhao B. Zhao C. Hu X. Design, synthesis and 3D-QSAR analysis of novel thiopyranopyrimidine derivatives as potential antitumor agents inhibiting A549 and Hela cancer cells. Eur. J. Med. Chem. 2020 185 111809 10.1016/j.ejmech.2019.111809 31683104
    [Google Scholar]
  145. Gan B.H. Gaynord J. Rowe S.M. Deingruber T. Spring D.R. The multifaceted nature of antimicrobial peptides: Current synthetic chemistry approaches and future directions. Chem. Soc. Rev. 2021 50 13 7820 7880 10.1039/D0CS00729C 34042120
    [Google Scholar]
  146. Ejeh S. Uzairu A. Shallangwa G.A. Abechi S.E. In silico design, drug-likeness and ADMET properties estimation of some substituted thienopyrimidines as HCV NS3/4A protease inhibitors. Chem Afr 2021 4 3 563 574 10.1007/s42250‑021‑00250‑y
    [Google Scholar]
  147. Bhole R.P. Bonde C.G. Bonde S.C. Chikhale R.V. Wavhale R.D. Pharmacophore model and atom-based 3D quantitative structure activity relationship (QSAR) of human immunodeficiency virus-1 (HIV-1) capsid assembly inhibitors. J. Biomol. Struct. Dyn. 2021 39 2 718 727 10.1080/07391102.2020.1715258 31928140
    [Google Scholar]
  148. Dhamodharan G. Mohan C.G. Machine learning models for predicting the activity of AChE and BACE1 dual inhibitors for the treatment of Alzheimer’s disease. Mol. Divers. 2022 26 3 1501 1517 10.1007/s11030‑021‑10282‑8 34327619
    [Google Scholar]
  149. Dhameliya T.M. Bhakhar K.A. Gajjar N.D. Patel K.A. Devani A.A. Hirani R.V. Recent advancements and developments in search of anti-tuberculosis agents: A quinquennial update and future directions. J. Mol. Struct. 2022 1248 131473 10.1016/j.molstruc.2021.131473
    [Google Scholar]
  150. Modi P. Patel S. Chhabria M. Discovery of newer pyrazole derivatives with potential anti-tubercular activity via 3D-QSAR based pharmacophore modelling, virtual screening, molecular docking and molecular dynamics simulation studies. Mol. Divers. 2023 27 4 1547 1566 10.1007/s11030‑022‑10511‑8 35969333
    [Google Scholar]
  151. Prem Kumar S.R. Shaikh I.A. Mahnashi M.H. Design, synthesis and computational approach to study novel pyrrole scaffolds as active inhibitors of enoyl ACP reductase (InhA) and Mycobacterium tuberculosis antagonists. J. Indian Chem. Soc. 2022 99 11 100674 10.1016/j.jics.2022.100674
    [Google Scholar]
  152. Zhang H. Huang J. Chen R. Ligand- and structure-based identification of novel CDK9 inhibitors for the potential treatment of leukemia. Bioorg. Med. Chem. 2022 72 116994 10.1016/j.bmc.2022.116994 36087428
    [Google Scholar]
  153. Banjare L. Singh Y. Verma S.K. Multifaceted 3D-QSAR analysis for the identification of pharmacophoric features of biphenyl analogues as aromatase inhibitors. J. Biomol. Struct. Dyn. 2023 41 4 1322 1341 10.1080/07391102.2021.2019122 34963408
    [Google Scholar]
  154. Raut V. Sarkate A. Bhandari D.S. A rational approach to anticancer drug design: 2D and 3D- QSAR, molecular docking and prediction of ADME properties using silico studies of thymidine phosphorylase inhibitors. Lett. Drug Des. Discov. 2022 19 10.2174/1570180819666220215115633
    [Google Scholar]
  155. Sokouti B. Hamzeh-Mivehroud M. 6D-QSAR for predicting biological activity of human aldose reductase inhibitors using quasar receptor surface modeling. BMC Chem. 2023 17 1 63 10.1186/s13065‑023‑00970‑x 37349775
    [Google Scholar]
  156. Mitra S. Halder A.K. Ghosh N. Mandal S.C. Cordeiro M.N.D.S. Multi-model in silico characterization of 3-benzamidobenzoic acid derivatives as partial agonists of Farnesoid X receptor in the management of NAFLD. Comput. Biol. Med. 2023 157 106789 10.1016/j.compbiomed.2023.106789 36963353
    [Google Scholar]
  157. Edache E. Uzairu A. Mamza P.A. Shallangwa G.A. Molecular phylogeny, sequence-based drug design, docking built virtual screening, dynamics simulations, and ADMET properties of thiazolino 2-pyridone amide derivatives as an inhibitor of Chlamydia trachomatis and SARS-CoV-2 protein. Turkish Computat Theoret Chem 2024 8 1 10 39 10.33435/tcandtc.1196019
    [Google Scholar]
  158. Aloui M El fadili M Mujwar S Design of novel potent selective survivin inhibitors using 2D-QSAR modeling, molecular docking, molecular dynamics, and ADMET properties of new MX-106 hydroxyquinoline scaffold derivatives. Heliyon 2024 10 19 e38383 10.1016/j.heliyon.2024.e38383 39397921
    [Google Scholar]
  159. El Fadili M. Er-rajy M. Imtara H. 3D-QSAR, ADME-Tox in silico prediction and molecular docking studies for modeling the analgesic activity against neuropathic pain of novel NR2B-selective NMDA receptor antagonists. Processes 2022 10 8 1462 10.3390/pr10081462
    [Google Scholar]
/content/journals/cpd/10.2174/0113816128392784250801044920
Loading
From Molecules to Medicine: Investigating the Evolution of Chemical Entities for Therapeutic Use through QSAR Analysis
Bentham Science Publishers ; https://doi.org/10.2174/0113816128392784250801044920
/content/journals/cpd/10.2174/0113816128392784250801044920
/content/journals/cpd/10.2174/0113816128392784250801044920
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: Free-Wilson ; descriptors ; Hansch ; physicochemical ; CoMSIA ; QSAR ; CoMFA

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test